HiMed International Medical Innovation Forum and Innovation Center Launch Ceremony Successfully Concluded

Recently, the “HiMed International Medical Innovation and Entrepreneurship Forum and Opening Ceremony of the International Innovation Center,” hosted by HiMed and co-organized by Yanxitang Medical Incubator, University of Shanghai for Science and Technology, Sino-Australian Technology Incubator, Sino-British Technology Incubator, and Healthcare Drinks, was grandly held in Zhangjiang, Pudong, Shanghai. The event received strong support from numerous domestic and international partners, and was jointly sponsored by OrbiMed, Yangpuwan Incubator, Huajian Medical, Topgen Life Sciences, China Medical City, HiMed Venture Capital, Aupu Biology, and Bank of Ningbo Shanghai Branch.

HiMed is a collaborative platform for medical innovation and entrepreneurship, jointly initiated by the Zhangjiang community. Over its five-year journey, it has embodied the wisdom and dedication of countless individuals. With the launch of the HiMed International Innovation Center and HiMed Accelerator, it is committed to becoming the premier destination for overseas innovation and entrepreneurship projects to rapidly establish their presence in China.

Australian Consulate-General in Shanghai Delegation Visits to Extend Congratulations

On the day of the event, Mr. Wu Jun, Deputy Director of the Zhangjiang Administration Bureau under the Shanghai Pilot Free Trade Zone Administrative Committee; Ms. Huang Lihong, Deputy Director of the Shanghai Science and Technology Innovation Center; Professor Gao Hengjun, Chairman of HiMed and Director of the National Engineering Research Center for Biochip Shanghai; Mr. Zhang Jie, Vice Chairman of HiMed and Partner at Angel Fund; Professor Song Chengli from the University of Shanghai for Science and Technology; Mr. Rob Scott, Partner at the China-Australia Technology Incubator; and Dr. Brandon Shaw, Partner at the China-UK Technology Incubator, among other leaders and industry experts, attended the event and delivered speeches. Mr. Li Dan, Commercial Consul of the Commercial Section of the Australian Consulate-General in Shanghai, together with commercial officials from the Australian Federal Government and various state governments, also extended their care and greetings.

Message from the Chairman of HiMed: Professor Gao Hengjun, Chairman of HiMed / Director of the Shanghai National Engineering Research Center for Biochip

Address by the Australian Guest: Mr. Li Dan, Commercial Consul, Commercial Office of the Consulate General of Australia in Shanghai, Austrade

Ms. Zhai Jingbo, Secretary-General of HiMed and Founder/General Manager of the Yanxitang Incubator, delivered a speech, expressing her heartfelt gratitude to the leaders, guests, partners, and entrepreneurs who attended the inauguration ceremony of the HiMed International Medical Innovation Center. Ms. Zhai stated that she would remain steadfast in her efforts to support overseas entrepreneurial projects and teams by providing the most favorable conditions and approaches to meet their needs in accessing the Chinese market, implementing business strategies, securing financing, and seeking partners.

Ms. Zhai Jingbo, General Manager of Yanxitang Incubator; Professor Song Chengli from the University of Shanghai for Science and Technology; Mr. Dong Binzhe, Co-founder of Medisicreat; Mr. Zhang Jie, Founding Partner of Haimaide Medical Angel Fund; Mr. Rob Scott, Partner at the China-Australia Technology Incubator; Dr. Brandon Shaw, Partner at the China-UK Technology Incubator; and Mr. Zhang Weiwei, Co-founder of Beijing Bozun Law Firm—these seven partners from the HiMed ecosystem are joining forces to accelerate the establishment of domestic and international innovation and entrepreneurship in China!

Ms. Zhai Jingbo, Secretary-General of HiMed and Founder/General Manager of Yanxitang Incubator; Mr. Li Dan, Commercial Consul of the Australian Consulate-General in Shanghai; Professor Gao Hengjun, Chairman of HiMed and Director of the Shanghai National Engineering Research Center for Biochip; Ms. Huang Lihong, Deputy Director of the Shanghai Science and Technology Innovation Center; Mr. Wu Jun, Deputy Director of the Zhangjiang Administration Bureau under the Shanghai Free Trade Zone Administrative Committee; Mr. Rob Scott, Partner of the China-Australia Technology Incubator; Dr. Brandon Shaw, Partner of the China-UK Technology Incubator; Professor Song Chengli from the University of Shanghai for Science and Technology; and Mr. Zhang Jie, Vice Chairman of HiMed and Partner of Angel Fund—these nine leaders jointly launched the HiMed International Accelerator and the International Medical Innovation Center.

Professor Cai Jiangnan, Director of the Center for Health Management and Policy at CEIBS and Adjunct Professor of Economics

Professor Masakazu Yagi, Specially Appointed Associate Professor, Biodesign Medical Innovation Department, Osaka University, Japan

Li Zhe, Deputy Director of the Management Committee of Taizhou Medical High-Tech Industrial Development Zone

Entrepreneurs from twelve companies, representing diverse countries and specialized sectors, gathered at HiMed to showcase their commercialization achievements. Following evaluations by a panel of 12 professional judges, the “Human and Veterinary Vaccines” project from Australia was awarded first place.

In addition, the following day, HiMed, as a co-host of Slush, led the camp participants to the Shanghai World Expo Exhibition Center to attend the 2019 Slush project pitch event, facilitating connections with domestic investors and corporate resources.

The roundtable discussion was moderated by Mr. Rob Scott, Partner at the China-Australia Technology Incubator. The panel featured Mr. Wu Hao, Deputy Director of Strategy and Business Development for Roche Diagnostics Asia Pacific; Mr. Pan Hui, General Manager of Avide Medical, a subsidiary of Huajian Medical (HK01931); Mr. Daniel Zhou, Executive Director at OrbiMed; and Mr. Xu Jianxin, Chairman of Aupu Bio. They engaged in an in-depth exchange from the perspectives of multinational giants, domestic listed companies, major cross-border capital firms, and incubators, addressing topics such as how China’s vast healthcare market is attracting the attention of overseas technology enterprises, strategies for entering the Chinese market, and criteria for selecting partners.